Workflow
股票期权激励计划
icon
Search documents
ST未名: 关于注销2023年股票期权激励计划第一个行权期届满未行权的股票期权的公告
Zheng Quan Zhi Xing· 2025-08-19 11:21
Core Viewpoint - The company announced the cancellation of unexercised stock options from the first exercise period of the 2023 stock option incentive plan, which has now expired, affecting a total of 16,617,396 stock options [4][6]. Summary by Sections 1. Approval Procedures and Plan Overview - The 2023 stock option incentive plan was approved by the board and relevant committees, with independent opinions provided by independent directors and legal opinions from Zhejiang Tianche Law Firm [1][2]. 2. Stock Option Grant and Conditions - The stock options were granted on May 29, 2023, with a total of 59 million options registered under the code 037368, and the exercise price set at 21.23 yuan per share [3][4]. 3. Cancellation of Stock Options - Due to 25 incentive targets leaving the company, 9,998,300 stock options were canceled. Additionally, 77 eligible incentive targets were allowed to exercise a total of 24,500,500 stock options [4][5]. 4. Impact of Cancellation - The cancellation of the stock options will not materially affect the company's financial status or operational results, nor will it impact the implementation of the 2024 equity incentive plan [6]. 5. Committee Opinions - The board's remuneration and assessment committee confirmed that the cancellation complies with relevant regulations and does not harm the interests of the company or its shareholders [6]. 6. Legal Opinions - Legal opinions confirmed that the company has fulfilled necessary approvals and disclosures regarding the cancellation of stock options, in accordance with applicable regulations [6].
ST未名: 半年报董事会决议公告
Zheng Quan Zhi Xing· 2025-08-19 11:12
Group 1 - The board meeting of Shandong Weiming Bio-Pharmaceutical Co., Ltd. was held on August 19, 2025, with all 11 directors participating [1] - The board approved the 2025 semi-annual report in full and summary, which was previously reviewed by the audit committee [2] - The board confirmed that there were no violations regarding the occupation of non-operating funds by controlling shareholders or related parties in the first half of 2025 [2][3] Group 2 - The board approved the cancellation of 16,617,396 stock options from the 2023 stock option incentive plan that were not exercised by 68 incentive objects by May 29, 2025 [2][3] - The cancellation of the stock options was within the authorization range granted by the company's first extraordinary general meeting in 2023 and did not require further shareholder approval [2][3]
ST未名: 浙江天册(深圳)律师事务所关于山东未名生物医药股份有限公司2023年股票期权激励计划注销部分股票期权事项的法律意见书
Zheng Quan Zhi Xing· 2025-08-19 11:09
Core Viewpoint - The legal opinion letter from Zhejiang Tiance (Shenzhen) Law Firm confirms that Shandong Weiming Bio-Pharmaceutical Co., Ltd. has complied with relevant laws and regulations regarding the cancellation of certain stock options under its 2023 stock option incentive plan [1][9]. Group 1: Implementation of the Incentive Plan - The company has implemented the 2023 stock option incentive plan and has obtained necessary approvals from the board and independent directors [3][4]. - The supervisory board has verified that the individuals included in the incentive plan meet the qualifications as per the Company Law and relevant regulations [6][7]. Group 2: Approval and Authorization for Cancellation - The company has conducted necessary meetings to approve the cancellation of stock options that were not exercised during the first exercise period [7][8]. - The first exercise period for the stock options is set from May 30, 2024, to May 29, 2025, with a total of 16,617,396 stock options remaining unexercised by the end of this period [8][9]. Group 3: Compliance with Regulations - The cancellation of stock options is in accordance with the provisions of the Management Measures and the draft incentive plan [8][9]. - The company is required to fulfill its information disclosure obligations and complete related procedures following the cancellation [9].
广东领益智造股份有限公司董事会薪酬与考核委员会关于2024年股票期权激励计划 预留授予部分激励对象名单公示情况说明及核查意见
Core Viewpoint - The company has publicly disclosed the names and positions of the incentive recipients for the 2024 stock option incentive plan, ensuring compliance with relevant regulations and confirming the legitimacy of the recipients [1][5]. Disclosure Details - Public disclosure content includes the names and positions of the incentive recipients for the 2024 stock option incentive plan [2] - Public disclosure period is from August 6, 2025, to August 15, 2025 [2] - The disclosure was made on the company's internal website, and no objections were raised during the public notice period [2] Verification Process - The company's Compensation and Assessment Committee verified the list of incentive recipients, including their identification documents, employment contracts, positions held, and appointment documents [3] Verification Opinions - The committee confirmed that the basic information of the incentive recipients is accurate, with no falsehoods or significant omissions [4] - All recipients are formal employees of the company or its subsidiaries, excluding directors, independent directors, senior management, and major shareholders [4] - The committee found no disqualifying circumstances for the recipients in the past 12 months, ensuring compliance with relevant laws and regulations [4] Conclusion - The Compensation and Assessment Committee concluded that the public disclosure process for the incentive recipients is legal and compliant, and the recipients meet all necessary conditions as per the relevant laws and regulations [5]
京北方信息技术股份有限公司
Core Viewpoint - The company, Jingbeifang Information Technology Co., Ltd., has released its 2025 semi-annual report, highlighting its financial performance and future development plans, with no significant changes in major shareholder structure or major events during the reporting period [1][5][6]. Company Basic Information - The company did not require retrospective adjustments or restatements of previous accounting data [4]. - There were no changes in the controlling shareholder or actual controller during the reporting period [5]. Financial Data and Indicators - The company reported a total fundraising amount of RMB 925.52 million from its initial public offering, with a net amount of RMB 865.55 million after deducting issuance costs [25]. - The company has a total of 4,017 million shares issued at a price of RMB 23.04 per share [25]. Board Meeting Resolutions - The board approved the semi-annual report and its summary, as well as the special report on the use of raised funds [6][8]. - The board authorized the chairman to approve loans up to RMB 800 million [41]. Asset Impairment Provision - The company has recognized an asset impairment provision of RMB 41.90 million for the first half of 2025, including provisions for inventory, contract assets, and accounts receivable [62][65][66].
光启技术股份有限公司 关于2025年股票期权激励计划首次授予登记完成的公告
Core Viewpoint - The company has completed the registration of its 2025 stock option incentive plan, which aims to attract and retain talent while aligning the interests of shareholders, the company, and the incentive recipients [2][19]. Group 1: Decision Process and Approval - The decision-making process for the incentive plan involved multiple meetings of the board and supervisory committee, with approvals obtained on June 9, 2025, and subsequent meetings held to finalize the plan [2][3][4]. - The plan was publicly announced, and no objections were raised during the public notice period [3][4]. Group 2: Initial Grant Details - The initial grant date for the stock options is set for July 22, 2025, with a total of 2.9302 million options granted to 133 recipients at an exercise price of 37.13 yuan per option [4][5]. - The registration of the stock options is expected to be completed by August 15, 2025 [4][5]. Group 3: Waiting Period and Exercise Arrangement - The waiting period for the stock options is structured over 12, 24, and 36 months from the completion of registration, with specific conditions under which options can be exercised [7][9]. - The exercise of options is restricted during certain periods, including prior to the announcement of financial reports and during significant events affecting stock prices [7][8]. Group 4: Performance Assessment Requirements - The incentive plan includes performance assessment requirements at both the company and individual levels, with company performance evaluated over the fiscal years 2025-2027 [12][13]. - If the company does not meet performance targets, the options for all recipients will be canceled for that period [12]. Group 5: Fair Value and Cost Implications - The fair value of the stock options is determined using the Black-Scholes model, with an estimated incentive cost of 20.8232 million yuan for the plan [16][17]. - The cost will be amortized over the duration of the incentive plan, impacting the company's operating performance [17][18]. Group 6: Impact of the Incentive Plan - The implementation of the incentive plan is expected to enhance the company's governance structure, attract and retain talent, and align the interests of various stakeholders towards the company's long-term development [19].
科沃斯: 关于2024年股票期权与限制性股票激励计划首次授予股票期权第一个行权期采用自主行权模式的提示性公告
Zheng Quan Zhi Xing· 2025-08-15 16:24
Core Viewpoint - The announcement details the implementation of the 2024 stock option and restricted stock incentive plan by Ecovacs Robotics Co., Ltd, highlighting the first exercise period using a self-exercise model for stock options [1][5]. Group 1: Incentive Plan Details - The board of directors approved the stock option incentive plan during the third meeting of the fourth board on August 14, 2025, following the authorization from the shareholders' meeting held on September 20, 2024 [1]. - The first exercise period for the stock options will adopt a self-exercise model, allowing eligible participants to exercise their options through the company's system [1][2]. - A total of 2,961,250 stock options are available for exercise [1]. Group 2: Adjustment Conditions - The exercise price of stock options will be adjusted in the event of dividends, capital reserve transfers, stock splits, or other corporate actions prior to the exercise [2][3]. - The company will announce the implementation of the self-exercise process three trading days before the start date of the exercise period [2]. Group 3: Allocation of Stock Options - The allocation of stock options includes specific amounts for key personnel, with the total granted options amounting to 1,184,500, representing 0.5152% of the total share capital [3]. - Key personnel include directors, vice presidents, and core technical staff, with individual allocations detailed in the announcement [3][4].
科沃斯: 君合律师事务所上海分所关于科沃斯机器人股份有限公司2024年股票期权与限制性股票激励计划注销部分已授予但尚未行权的股票期权及首次授予股票期权第一个行权期行权条件成就等相关事项的法律意见书
Zheng Quan Zhi Xing· 2025-08-15 16:24
中国上海石门一路 288 号兴业太古汇香港兴业中心一座 26 层 邮编:200041 电话:(86-21)5298 5488 传真:(86-21)5298 5492 法律意见书 致:科沃斯机器人股份有限公司 君合律师事务所上海分所(以下简称"本所")为具有从事法律业务资格的 律师事务所分所。本所接受科沃斯机器人股份有限公司(以下简称"公司"或 "科沃斯")的委托,委派本所律师以特聘法律顾问的身份,就公司 2024 年股 票期权与限制性股票激励计划(以下简称"本次激励计划")有关事宜,包括注 销本次激励计划部分已授予但尚未行权的股票期权(以下简称"本次注销")及 本次激励计划首次授予股票期权第一个行权期行权条件成就(以下简称"本次行 权")等相关事宜出具本法律意见书。 本法律意见书系根据《中华人民共和国公司法》 (以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")、中国证券监督管理委 员会(以下简称"中国证监会")颁布的《上市公司股权激励管理办法》(以下 简称"《管理办法》")等在本法律意见书出具日以前中国(仅为出具本法律意 见书之目的,不包括香港特别行政区、澳门特别行政区和台湾地区 ...
中远海能: 中远海能2023年股票期权激励计划管理办法(建议修订稿)
Zheng Quan Zhi Xing· 2025-08-15 12:16
Core Points - The article outlines the management and organizational structure of the stock option incentive plan for China COSCO Shipping Energy Transportation Co., Ltd, detailing the roles of various committees and departments involved in the plan's execution [1][2][3] Group 1: Management and Organizational Structure - The stock option incentive plan is managed by the shareholders' meeting, the board of directors, and the remuneration and assessment committee [1] - The board of directors is responsible for reviewing and approving the stock option incentive plan and its amendments, as well as overseeing the granting of stock options [1][2] - The remuneration and assessment committee drafts the stock option incentive plan and evaluates the performance conditions for the granted options [1][2][3] Group 2: Execution and Responsibilities - The execution departments include the board office/securities affairs department, financial management department, human resources/organization department, and legal and risk management department [2] - The board office/securities affairs department is responsible for information disclosure and tracking the implementation of the incentive plan [2] - The financial management department analyzes the achievement of annual performance indicators and assesses the fulfillment of performance conditions [2][3] Group 3: Approval and Implementation Procedures - The remuneration and assessment committee drafts the stock option incentive plan and submits it to the board for review after consulting with COSCO Shipping Group [3] - The board must approve the plan, and independent directors and the supervisory board must provide opinions on its benefits to the company [3] - The shareholders' meeting must approve the plan with a two-thirds majority vote, and the plan can only be implemented after this approval [3][4] Group 4: Granting and Exercising Options - The granting process involves the remuneration and assessment committee proposing a grant plan, which is then approved by the board [4][5] - The exercise of options requires the incentive recipients to submit an application, which is reviewed by the remuneration and assessment committee [6] - The company must disclose the exercise information and handle the necessary registration and settlement procedures [6][7] Group 5: Special Circumstances and Dispute Resolution - The plan outlines conditions under which the incentive plan may be terminated, including significant financial discrepancies or legal issues [7][8] - Special circumstances affecting individual recipients, such as misconduct or retirement, are also addressed, detailing how their options will be handled [8][9] - Disputes arising from the execution of the incentive plan should be resolved through negotiation or arbitration [10] Group 6: Financial Accounting and Tax Treatment - The accounting treatment for stock options is based on relevant accounting standards, with costs recognized over the vesting period [10][11] - Tax obligations for recipients of stock options are specified, with the company responsible for withholding and remitting taxes [10][11] Group 7: Internal Control and Supervision - The board of directors serves as the final authority for interpreting and approving the incentive plan [11][12] - Various departments are assigned specific responsibilities to ensure effective oversight and compliance with regulations [11][12]
煌上煌: 关于2023年股票期权激励计划部分股票期权注销完成的公告
Zheng Quan Zhi Xing· 2025-08-15 08:18
江西煌上煌集团食品股份有限公司(以下简称"公司")于 2025 年 8 月 7 日召开了第六届董事会第十五次会议和第六届监事会第十五次会议,审议通过了《关 于 2023 年股票期权激励计划第二个行权期行权条件未成就及注销部分股票期权 的议案》,根据立信会计师事务所(特殊普通合伙)出具的 2022 年度、2024 年 度审计报告,公司 2024 年度营业收入 1,739,291,324.72 元,较 2022 年下降 期权激励计划第二个行权期的公司业绩考核目标未达成。因此本激励计划所有激 励对象(不含不再符合激励条件人员)授予的股票期权第二个行权期所对应的全 部股票期权 3,177,000 份,由公司注销;因 20 名授予股票期权的激励对象已离 职,不再具备激励对象资格,根据公司《2023 年股票期权激励计划(草案)》相 关规定,注销相关离职人员已获授但尚未行权的股票期权合计 891,320 份。上述 需注销的股票期权数量合计 4,068,320 份。具体内容详见刊登于 2025 年 8 月 8 日指定信息披露媒体《中国证券报》《证券时报》《上海证券报》《证券日报》和 巨潮资讯网站(http://www.cni ...